Andere talen Kezar Life Sciences, Inc.

Aandelen

KZR

US49372L1008

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,8574 ^USD	+0,32%		+6,52%	-9,50%

14/03	Kezar Life Sciences, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
14/03	Kezar Life Sciences, Inc. rapporteert resultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	08/04
Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update	14/03
Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	08/03
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis	27/02
Kezar Life Sciences, Inc.(NasdaqGS:KZR) dropped from NASDAQ Biotechnology Index	15/12
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)	04/12
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference	21/11
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update	13/11
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	09/11
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	03/11
KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	10-10-23
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	10-10-23
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	09-10-23
North American Morning Briefing : Investors Await -2-	06-10-23
Kezar Life Sciences Launches Restructuring Program, Cuts Workforce, Names New CEO	03-10-23
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer	03-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kezar Life Sciences, Inc.

Aandelen

KZR

US49372L1008

Andere talen

Filters